Design and rationale for the life after stopping tyrosine kinase inhibitors (LAST) study, a prospective, single-group longitudinal study in patients with chronic myeloid leukemia

Design and rationale for the life after stopping tyrosine kinase inhibitors (LAST) study, a prospective, single-group longitudinal study in patients with chronic myeloid leukemia

Abstract Background Treatment of chronic myeloid leukemia with a tyrosine kinase inhibitor (TKI) offers significant improvements over previous treatments in terms of survival and toxicity yet nevertheless is associated with reduced health-related quality of life and very high cost. Several small stu...

Full description

Bibliographic Details
Main Authors: Ehab Atallah, Charles A. Schiffer, Kevin P. Weinfurt, Mei-Jie Zhang, Jerald P. Radich, Vivian G. Oehler, Javier Pinilla-Ibarz, Michael W. N. Deininger, Li Lin, Richard A. Larson, Michael J. Mauro, Joseph O. Moore, Ellen K. Ritchie, Neil P. Shah, Richard T. Silver, Martha Wadleigh, Jorge Cortes, James Thompson, Jessica Guhl, Mary M. Horowitz, Kathryn E. Flynn
Format: Article
Language:English
Published: BMC 2018-04-01
Series:BMC Cancer
Subjects:
Chronic myeloid leukemia
Oncology
Targeted therapy
Tyrosine kinase inhibitor
Discontinuation
Clinical trial
Online Access:http://link.springer.com/article/10.1186/s12885-018-4273-1

Internet

http://link.springer.com/article/10.1186/s12885-018-4273-1

Similar Items